Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"

Launched by FUNDACIÓN SOCIEDAD ESPAÑOLA DE ONCOLOGIA MÉDICA · Feb 25, 2019

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the connection between blood clots (thromboembolism) and cancer. Researchers want to learn more about patients who have been diagnosed with cancer and also experienced a blood clot either shortly before or anytime after their cancer diagnosis. The goal is to gather information from different medical centers to better understand how these two conditions are related.

To be eligible for the study, participants must be over 18 years old and have a confirmed diagnosis of cancer. They should have experienced a blood clot that was confirmed using medical imaging techniques, either in the month leading up to their cancer diagnosis or any time afterward. Participants will be asked to sign a consent form, and they will only be included in the study once, meaning that if they have a second blood clot, it will be treated as a separate event. If you or someone you know fits these criteria, joining this study could help improve understanding of how cancer and blood clots are linked, potentially benefiting future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years of age with a histologically confirmed diagnosis of malignant tumor.
• • Venous or arterial thromboembolism episode, symptomatic or incidental, in the month prior or any time after the cancer diagnosis and in the three previous months to enrollment, confirmed with an imaging technique: Doppler echocardiography, computed tomography (CT) angiography, etc.
• • Signing of informed consent.
• Exclusion Criteria:
• • Clinical diagnosis of thromboembolic event without radiological confirmation.
• • Presenting a single episode of superficial thrombophlebitis without association with another thromboembolic event.
• • Each patient will be recorded just once, and therefore a second thromboembolic event will be considered a rethrombosis and will be recorded as such. Patients with a rethrombosis and a previous thromboembolic event before the start of the study in each center will not be able to be included.